Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid by unknown
CASE REPORT Open Access
Disease stabilization with pembrolizumab
for metastatic acral melanoma in the
setting of autoimmune bullous pemphigoid
Kristen M. Beck1,2†, Joanna Dong3†, Larisa J. Geskin2, Vincent P. Beltrani2, Richard G. Phelps3,4, Richard D. Carvajal1,
Gary Schwartz1, Yvonne M. Saenger1* and Robyn D. Gartrell1
Abstract
Background: To date, patients with pre-existing autoimmune conditions have been excluded from immunotherapy
trials out of concern for severe autoimmune exacerbations.
Case Presentation: We describe the first case of a patient with metastatic cKIT mutated acral melanoma, brain
metastasis, and pre-existing severe autoimmune bullous pemphigoid (BP) with stable and asymptomatic disease
10 months after treatment with pembrolizumab. The patient experienced severe BP exacerbation after therapy with
ipilimumab requiring systemic immune suppression, but nonetheless pembrolizumab was administered on further
disease progression.
Conclusions: This case suggests that pembrolizumab may confer more benefit than risk even in patients with known
severe autoimmune conditions who require intermittent systemic immunosuppression.
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Background
Novel checkpoint blockade immunotherapies offer dur-
able survival benefit for metastatic melanoma, although
they remain of debatable benefit for patients who also
have chronic autoimmune conditions because they confer
significant risk of severe autoimmune toxicity. Incidences
of autoimmune thyroiditis, hypophysitis, pneumonitis,
hepatitis, nephritis, arthritis, tenosynovitis, and bullous
pemphigoid (BP) after immune checkpoint blockade are
well documented and have raised concern for use of
immunotherapies in melanoma patients whose comorbid-
ities predispose them to immune related adverse events
(irAE) [1–5].
Current FDA-approved agents for unresectable meta-
static melanoma include chemotherapy, BRAF inhibi-
tors, MEK inhibitors, ipilimumab, a CTLA-4 inhibitor,
and anti-PD1 antibodies pembolizumab and nivolumab.
The current consensus among medical oncologists in
the United States is that anti-PD1 agents should be in-
cluded as first-line therapy, especially given the higher
response rate and lower toxicity profile when compared
to ipilimumab, and this is now reflected in National Com-
prehensive Cancer Network (NCCN) guidelines [1, 6, 7].
Checkpoint inhibition with anti-PD1 monoclonal antibodies
increases overall survival in metastatic melanoma, and has
demonstrated response in 25–40 % of patients [1, 8, 9]. In
contrast, traditional chemotherapies (e.g., dacarbazine, tem-
ozolomide, fotemustine) have been of little efficacy for
metastatic melanoma and are associated with a median
survival of less than 9 months, with only a small minority
(5–10 %) of patients achieving long-term survival of 5 years
or more [9, 10]. Despite this, chemotherapy may be the only
available therapeutic option for patients whose tumor does
not express a readily targetable mutation and who cannot
tolerate immunotherapy. Thus, chemotherapy may be
recommended for patients with a history of severe auto-
immune disease and metastatic melanoma since little is
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known about the safety and efficacy of PD-1 inhibitors in
this population. Here, we report a case describing the effect-
ive use of a PD-1 inhibitor in stabilizing metastatic brain,
lung, and bone lesions in a patient with a history of severe
and concurrent BP and widely metastatic acral melanoma.
Case presentation
A 72 year-old male was diagnosed with subungual melan-
oma removed from the nail bed of his right thumb in
2007 with a depth of 1.0 mm at the site of prior melanoma
in situ dating back to 1981. In 2009, he had a recurrence
at the same site extending down his digit and necessitating
amputation of the distal phalanx. Resected sentinel nodes
showed a melan-A positive focus of hyperchromatic atyp-
ical melanocytes in one node and S-100 positive dendritic
cell staining in the other two nodes. Due to potential sur-
gical complications and patient preference for observation,
complete dissection was not performed.
In 2010, the patient presented with multiple bullae on the
back. The diagnosis of BP was made by a skin biopsy and
clinical and pathological correlation [Fig. 1]. Disease activity
was managed with high dose oral prednisone with eventual
taper and disease remission after one year. In 2011, the pa-
tient noticed a new lump in his right axilla. Pathology con-
firmed malignant melanoma with a cKIT mutation (L576P
in exon 11) completely replacing a lymph node. Positron-
emission tomography (PET) revealed lung nodules, suspi-
cious for metastatic disease. The patient declined a recom-
mended lung biopsy and, after discussion of the risk of BP
flare, therapy was initiated with ipilimumab at 3 mg/kg.
Several days after the second dose, he experienced severe
exacerbation of his BP with mucous membrane involve-
ment for which he was hospitalized and treated with a 9-
week course of 60 mg of prednisone. He subsequently
maintained control of BP with 15 mg of prednisone daily.
After discontinuing ipilimumab, computed tomographic
(CT) scan showed numerous enlarging bilateral pulmonary
lesions and mediastinal lymphadenopathy. Magnetic reson-
ance imaging (MRI) of the brain showed small volume
brain metastases to the left internal auditory canal and the
inferior aspect of right cerebellum, which were clinically
asymptomatic. He declined radiation therapy for the brain
lesion and began therapy with nilotinib, a small molecule
tyrosine kinase inhibitor for cKIT mutant melanoma, at a
dose of 400 mg twice daily. After three weeks of treatment,
CT scan showed interval improvement in previously noted
mediastinal lymphadenopathy. Over the following year, his
nilotinib dose was reduced to 200 mg BID or held due to
elevated liver function tests and prolonged QT interval.
During this time, imaging showed interval progression of
his brain and lung metastases. He received stereotactic ra-
diosurgery to the right cerebellar lesion with subsequent
stabilization of the brain lesions on imaging.
In 2014, he developed new osseous metastases to the
thoracic vertebrae. Nilotinib was discontinued and he
received palliative radiation to the spine for local disease
control. At this time the patient completed prednisone
taper without flare of his BP. The patient then received
pembrolizumab, at a dose of 2 mg/kg given every three
weeks. The first 3 doses of pembrolizumab were well tol-
erated with minimal bullous eruption, which was con-
trolled with clobetasol 0.05 % topical cream. Imaging
after 10 weeks of treatment showed essentially stable
disease, and a cutaneous metastasis on his wrist flat-
tened and regressed [Fig. 2]. However, following the
fourth cycle, the patient developed a severe BP flare
resulting in discontinuation of pembrolizumab and the
start of oral prednisone at 60 mg a day. Over the next
three months, the patient’s BP lesions had resolved and
prednisone was tapered off, allowing for a fifth cycle of
pembrolizumab [Fig. 3]. The patient again developed a
flare of BP requiring patient to stop anti-PD1 and again
Fig. 1 Biopsy of the patient’s skin lesions. Haematoxylin and eosin stain
reveals subepidermal bulla as well as fibrin net, numerous eosinophils,
perivascular mixed infiltrate, and well-preserved dermal papillae within
the bulla cavity Fig. 2 Cutaneous melanoma lesion with surrounding vitiligo
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start prednisone at the same dose. He had improvement
of skin lesions but was unable to taper below 15 mg
without worsening symptoms. One year following initial
treatment with pembrolizumab, scans show stable disease
with unchanged brain, pulmonary, and osseous metasta-
ses. Clinically, the patient feels well and denies symptoms
related to his metastases. He is undergoing continued
monitoring of both his metastatic melanoma and his BP.
Discussion and conclusions
Patients with autoimmune disease have been excluded
from checkpoint inhibitor trials out of concern for auto-
immune exacerbation due to therapeutic blockade of
checkpoint receptors. To our knowledge, this is the first
description of a patient with pre-existing and active auto-
immune disease treated with pembrolizumab resulting in
disease stabilization. As expected, ipilimumab and pem-
brolizumab treatment induced autoimmune disease flares
in the patient. While the flare from ipilimumab was severe
enough to warrant extreme caution regarding further ad-
ministration of this agent, subsequent administration of
pembrolizumab with a limited dose scheduling resulted in
clinically meaningful disease control while autoimmune
symptoms were controlled with oral steroids when
needed. Notably, even modified intermittent use of PD-1
inhibitor resulted in stabilization of his melanoma in the
presence of numerous markers of poor prognosis.
BP is a subepidermal blistering disease characterized
by an autoimmune response to hemidesmosomal pro-
teins within the dermal-epidermal junction that occurs
primarily in elderly adults. It presents with pruritic urti-
carial plaques and tense subepithelial blisters on the skin
[11]. The pathophysiology is similar to that of other
autoimmune diseases: breakdown of T and B-cell toler-
ance to BP antigens leads to autoantibody production
and subsequent blister induction [12]. The initiating
trigger for the autoimmune response is yet unclear,
though certain medications or infections have been asso-
ciated [13, 14]. Although data is conflicting, there is also
an association between BP and malignancy, suggesting
that BP may arise as a paraneoplastic condition [15]. In
this case, the patient’s diagnosis of BP predated his can-
cer diagnosis, making the possibility of a paraneoplastic
bullous pemphigoid less likely. There is one prior case
report of a patient developing new-onset BP during
pembrolizumab therapy, without resumption of further
cycles after immunosuppressant therapy, and subsequent
progression of brain metastasis [5]. In this case, BP exac-
erbations were clearly temporally associated with
immunotherapy, but adequate control of BP in a multi-
disciplinary fashion allowed for continuation of poten-
tially life-prolonging medication.
The major goal of checkpoint blockade with PD-1 and
CTLA-4 is to interfere with the ability of tumors to
stimulate inhibitory surface receptors on T cells and
generate potent tumor immunity [16]. However, given
that these receptors are critical to maintaining immuno-
logic homeostasis, there is theoretically concern that
these therapies pose significant risk to patients with pre-
existing conditions of autoimmunity. The differences be-
tween CTLA-4 and PD-1 in both expression and mech-
anism of action are thought to contribute to the
differences in autoimmune side effects of their respective
therapeutic inhibitors. CTLA-4 is expressed by T-cells
throughout the body, and its ligand is expressed by anti-
gen presenting cells. CTLA-4 is also highly expressed on
Foxp3+CD4+ regulatory T cells (Tregs) and there is ample
evidence that CLTA-4 is a locus of susceptibility to auto-
immune disease. In contrast, PD-1 expression is limited
primarily to exhausted T-cells and its ligand is found on
tumor cells. PD-1 is therefore more antigen-specific than
CTLA-4. The therapeutic blockade of CTLA-4 on Tregs
profoundly impairs the ability of Tregs to attenuate T cell
activation required for peripheral tolerance. Therefore,
PD-1 blockade is associated with milder autoimmune side
effects, in comparison to the severe, nonspecific auto-
immune side effects of CLTA-4 blockade. Also for these
reasons, autoimmune flares on anti-CTLA-4 therapy do
not necessarily recur with subsequent anti-PD1 therapy. A
recent study of patients with irAE on ipilimumab exhib-
ited unrelated or nonexistent irAEs when subsequently
treated with pembrolizumab [17]. Our case is consistent
with this report, as the patient experienced severe irAE re-
quiring hospitalization after treatment with ipilimumab,
but was able to tolerate pembrolizumab with milder irAE.
Nevertheless, dermatologic adverse events are among
the most common irAEs in patients treated with all
checkpoint inhibitors. The rash observed with check-
point inhibitors is most often reticular, edematous, and
maculopapular [18]. It may be asymptomatic or pruritic.
Fig. 3 Clinical picture of ruptured bullae, erosions, and crusts of mild
bullous pemphigoid exacerbation on low-dose corticosteroid treatment
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Current guidelines for the management of irAEs gener-
ally recommend immunosuppression with corticoste-
roids as well interruption of the checkpoint inhibitor
treatment cycle until symptoms or toxicity are grade 1
(mild) or less [19]. Grade 1 and 2 (mild and moderate)
rashes can be treated with topical corticosteroids and
oral antihistamines. Grade 1 and 2 oral mucositis can
often be managed with oral corticosteroid rinses and
lidocaine. For grade 3 or 4 (severe or life-threatening)
dermatologic irAEs, the checkpoint inhibitor should be
discontinued and systemic corticosteroids are recom-
mended. Prompt referral to a dermatologist and biopsy
is indicated for any rash that does not respond to topical
corticosteroids or that presents with bullous lesions. The
differential diagnosis should include Stevens-Johnson syn-
drome and toxic epidermal necrolysis, life-threatening
emergencies which have been reported in rare cases.
The optimal scheduling of CTLA-4 and PD-1 inhibition
for best survival rate and minimal irAEs in the setting of
concurrent autoimmune disease is not yet known. While
2 mg/kg every 3 weeks is recommended for pembrolizu-
mab, clinical trials have incorporated higher doses and
more frequent scheduling, which may account for the
high rate of irAE seen. It is possible that such irAEs are
dose-dependent. The kinetics of immunotherapy are such
that responses may develop after many weeks and months
of therapy, with benefits lasting even after discontinuation
[20]. Responses to immunotherapy may also develop after
only a few treatments. There is a reported case of tumor
eradication after only one treatment with combination
anti-PD1 and anti-CTLA-4 immunotherapies [21]. Im-
portantly, based a study of 576 melanoma patients pooled
from nivolumab clinical trials, immunosuppressive treat-
ment for irAEs does not appear to impact outcomes [22].
As in our patient who received less frequent dosing due to
autoimmune exacerbation, pembrolizumab with a lower
frequency of dosing is a reasonable strategy for patients
with refractory metastatic melanoma and concurrent
autoimmune disease. Thus, this case illustrates that dosing
and or frequency of immunotherapy may need to be indi-
vidualized based on autoimmune toxicity.
Pembrolizumab’s ability to halt progression of disease
and promote longer-term survival is also notable in this
case because of this patient’s numerous poor prognostic
factors. Acral melanoma, an uncommon subtype of
melanoma with a classically poor prognosis and more ag-
gressive invasiveness, has exhibited encouraging respon-
siveness to immunotherapy [23, 24]. cKIT mutations have
been implicated as an independent risk factor for poor
prognosis, and patients with cKIT mutations have shown
lower rates of survival compared to those without cKIT
mutations [25]. Brain metastases in melanoma have an ex-
tremely poor prognosis, though there is increasing evi-
dence on the efficacy of pembrolizumab [26].
It is of paramount importance to develop strategies for
use of immunotherapy to improve the chances of achiev-
ing durable benefit and long-term survival in patients with
autoimmune conditions and/or who require chronic im-
munosuppression. Our case advocates for pembrolizumab
treatment for patients with melanoma and refractory brain
metastases who have progressed on other therapies. Given
the life-threatening nature of advanced melanoma and the
potential survival benefit conferred by pembrolizumab,
treatment with pembrolizumab may be a reasonable op-
tion in the setting of autoimmune conditions, with careful
consideration of dosages and cycle frequency.
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